01.02.2012 19:35 Uhr, Quelle: Wallstreet online

Affinium Pharmaceuticals, Ltd., Announces First Patient Dosed With Oral AFN-1252 in a Phase 2 Clinical Trial for Acute Bacterial Skin & Skin Structure Infections

AUSTIN, Texas and TORONTO, February 1, 2012 /PRNewswire/ Affinium Pharmaceuticals announced today dosing of the first patient in a multi-center Phase 2 clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections …

Weiterlesen bei Wallstreet online